CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Sera Prognostics Q3 PreTRM revenue jumps 163% on test volume growth

By Reuters News


Overview

  • U.S. pregnancy diagnostics firm's Q3 PreTRM test revenue rose 163% yr/yr

  • PreTRM test volumes increased 54% sequentially and nearly five-fold from Q1 2026

  • Operating expenses declined 11% sequentially after cost reduction initiatives in June 2026


Outlook

  • Company expects increased test volume in fiscal year 2027

  • Sera Prognostics is in discussions for a multi-state, multi-thousand-patient pilot with a large insurer, planned for fiscal 2027

  • Company has started CE Mark submission for PreTRM Global in Europe


Result Drivers

  • TEST VOLUME GROWTH - PreTRM test volumes rose 54% sequentially and nearly five-fold from Q1 2026, driven by PRIME study publication and commercial team expansion

  • LOWER AVERAGE SELLING PRICES - Revenue growth was limited by a higher mix of low or non-reimbursed tests, which reduced average selling prices

  • MEDICAID COVERAGE EXPANSION - Florida and Illinois added PreTRM to Medicaid coverage, expanding access to approximately 7 mln covered Medicaid lives


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 PreTRM Test Revenue

$42,000

Q3 Net Loss

$8.05 mln

Q3 Income from Operations

-$8.89 mln

Q3 Loss Per Basic Share

$0.16

Q3 Operating Expenses

$8.93 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the business support services peer group is "buy."

  • Wall Street's median 12-month price target for Sera Prognostics, Inc. is $5.50, about 185% above its November 3 closing price of $1.93


Reuters Recommended Reads

  • Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance

  • Nov 3 - Amgen Q3 revenue beats expectations on higher volumes

  • Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.